title: Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
abstract: OBJECTIVE
  The (111)In-capromab pendetide scan (ProstaScint; Cytogen Corp., Princeton NJ) is approved by the Food and Drug Administration to evaluate increasing prostate-specific antigen (PSA) levels after radical prostatectomy. This study evaluated the role of prostate bed (111)In-capromab pendetide scan findings to predict response to salvage radiotherapy (RT).
  
  
  METHODS
  Forty patients who had PSA recurrence after radical prostatectomy and a (111)In-capromab pendetide scan immediately before salvage prostate bed RT (median, 66 Gy) were identified from the Duke Prostate Center database. Patients with distant uptake of capromab pendetide or long-term androgen deprivation therapy were excluded. Median follow-up after salvage RT was 2.7 years. Patient demographic, clinical, and pathologic characteristics; PSA values; and (111)In-capromab pendetide scan results were retrospectively analyzed. A PSA failure after salvage RT was defined as PSA level greater than 0.2 ng/ml. Data were combined with other published results in a secondary pooled analysis of 106 patients.
  
  
  RESULTS
  (111)In-Capromab pendetide findings included 20 patients with negative scan results and 20 with locally positive scan results. Two-year progression-free survival rates were 60% for patients with a negative scan result and 74% for those with a locally positive scan result (p = 0.49). Combined analysis did not show a difference in outcome based on local (111)In-capromab pendetide scan result.
  
  
  CONCLUSIONS
  For patients without distant signal detected by using (111)In-capromab pendetide scan, patients with locally positive scan findings did not have statistically different progression-free survival than those with a negative scan result, suggesting that salvage RT may be successful in patients with either a locally positive or negative (111)In-capromab pendetide scan result.
authors.affiliation: Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA. koont005@mc.duke.edu
authors.forename: Bridget F
authors.initials: BF
authors.lastname: Koontz
authors.forename: Vladimir
authors.initials: V
authors.lastname: Mouraviev
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Johnson
authors.forename: Janice
authors.initials: J
authors.lastname: Mayes
authors.forename: Stephanie H
authors.initials: SH
authors.lastname: Chen
authors.forename: Terence Z
authors.initials: TZ
authors.lastname: Wong
authors.forename: Mitchell S
authors.initials: MS
authors.lastname: Anscher
authors.forename: Leon
authors.initials: L
authors.lastname: Sun
authors.forename: Judd
authors.initials: J
authors.lastname: Moul
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Polascik
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal; D005500:Follow-Up Studies; D006801:Humans; D007202:Indicators and Reagents; D007205:Indium Radioisotopes; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000532:radiotherapy / Q000601:surgery; D011877:Radionuclide Imaging; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate
chemical_list: D000911:Antibodies, Monoclonal; D007202:Indicators and Reagents; D007205:Indium Radioisotopes; C101315:Capromab Pendetide; D017430:Prostate-Specific Antigen